Abstract: Provided herein are methods of producing a photoreceptor precursor (PRP) cell population derived from stem cells. Further provided herein are methods of using the PRP cell populations, such as for therapeutics.

Abstract: Provided herein are methods of producing a photoreceptor precursor (PRP) cell population derived from stem cells. Further provided herein are methods of using the PRP cell populations, such as for therapeutics.

Abstract: Provided herein are methods of producing an RPE cell population from a starting cell suspension, such as a single cell suspension, of pluripotent stem cells (PSCs). Such a method may comprise culturing the starting single cell suspension of PSCs in differentiation media to produce human RPE cells.

Abstract: Provided herein are methods of enriching a retinal pigment epithelium (RPE) cell population derived from stem cells. Such a method may comprise removing contaminating cells through the depletion of CD24 positive cells, CD56 positive cells, and/or CD90 positive cells from a starting population of RPE cells.

Abstract: Provided herein are methods of enriching a retinal pigment epithelium (RPE) cell population derived from stem cells. Such a method may comprise removing contaminating cells through the depletion of CD24 positive cells, CD56 positive cells, and/or CD90 positive cells from a starting population of RPE cells.

Abstract: Provided herein are methods for the production of antigen-specific effector T cells and NK cells from pluripotent stem cells which express a chimeric antigen receptor (CAR). Further provided herein are methods for the adoptive cell therapy by administering the effector T cells and/or NK cells provided herein.

Abstract: Provided herein are methods for the efficient in vitro differentiation of somatic cell-derived pluripotent stem cells to hematopoietic precursor cells, and the further differentiation of the hematopoietic precursor cells into immune cells of various myeloid or lymphoid lineages, particularly T cells, NK cells, and dendritic cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the hematopoietic precursor cells.

Abstract: Provided herein are methods of producing a photoreceptor precursor (PRP) cell population derived from stem cells. Further provided herein are methods of using the PRP cell populations, such as for therapeutics.

Abstract: Provided herein are methods of producing an RPE cell population from a starting cell suspension, such as a single cell suspension, of pluripotent stem cells (PSCs). Such a method may comprise culturing the starting single cell suspension of PSCs in differentiation media to produce human RPE cells.

Abstract: Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from peripheral blood cells, such as human blood progenitor cells, using episomal reprogramming and feeder-free or xeno-free conditions. In certain embodiments, the invention provides novel methods for improving overall reprogramming efficiency with low number of blood progenitor cells.

Abstract: Midbrain dopaminergic neuronal precursor cells that can be used to treat a brain disorder are provided herein. Improved mono-SMAD methods are provided that can be used to differentiate pluripotent cells into midbrain dopaminergic (DA) neurons or midbrain neuronal precursors. In some aspects, methods are provided for mono-SMAD culture protocols and culture durations that can be used to generate dopaminergic neuronal precursor cells that have significantly improved properties for the treatment of a brain disorder such as, e.g., Parkinson's disease. Methods of treating Parkinson's disease and other brain diseases with the midbrain dopaminergic neuronal precursor cells are also provided.

Abstract: The present disclosure provides iPSC-derived microglia comprising a protective CD33 allele. Further provided herein are assays for screening analytes and genes associated with the protective CD33 allele.

Abstract: Provided herein are methods for producing quiescent cardiac fibroblast cells from pluripotent stem cells. Further provided herein are microtissue compositions comprising the cardiac fibroblast cells with endothelial cells and cardiomyocytes.

Abstract: Provided for herein is a method of cell transplantation using an injection attachment having a hub containing a plurality of cells and a cannula extending from a distal end of the hub. The method includes orienting the injection attachment such that the cannula points downwardly until the plurality of cells settle together proximate the distal end, inserting the cannula into a tissue of a subject, and injecting the volume of cells into the tissue of the subject using the injection attachment.

Abstract: The present disclosure provides iPSC-derived dopaminergic neurons comprised disease-associated mutations. Further provided herein are methods for using the iPSC-derived dopaminergic neurons for the study of neuroinflammation, such as to identify novel targets, biomarkers, and therapeutic agents for the diagnosis, prognosis, and treatment of neurodegenerative diseases. Further provided herein are assays for studying neuroinflammation using the present cell culture models.

Abstract: The present disclosure provides method for producing neural precursor cells with a glial bias from induced pluripotent cells and further differentiating the neural precursor cells to astrocytes. Further provided herein are methods for the use of the astrocytes for screening assays, models mimicking the human brain, and cell therapy.

Abstract: Provided herein are methods of producing a distinct bilayer culture of retinal epithelial cells (RPE) with photoreceptor cells and/or photoreceptor precursor cells (PR/PRP). Further provided herein is a therapy comprising transplantation of the RPE and PR/PRP bilayer as well as methods for testing candidate drugs using the bilayer.

Abstract: Provided herein is a dual cell aggregate culture of retinal epithelial cells and photoreceptors for use as a research tool, such as the screening of compounds or model for study of retinal diseases, as well as a therapeutic for treating ocular diseases.

Abstract: The present disclosure provides multicellular culture models for the study of neuroinflammation, such as to identify novel targets, biomarkers, and therapeutic agents for the diagnosis, prognosis, and treatment of neurodegenerative diseases. Further provided herein are assays for studying neuroinflammation using the present cell culture models.

Abstract: Provided herein are methods for the differentiation of pluripotent stem cells to committed cardiac progenitor cells. Further provided herein are methods for the use of the committed cardiac progenitor cells in the treatment of cardiac disorders.